Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova has filed its Q3 FY26 financial results with NSE for the quarter ended December 31, 2025. The filing is a standard regulatory disclosure under listing obligations, but the actual revenue, profit, and margin numbers are not included in the excerpt provided. Retail investors should refer to the detailed results PDF on the NSE/BSE corporate filings page or the company's investor section to review segment-wise performance of its pharmaceutical, radiopharma, and contract manufacturing businesses. The standalone vs consolidated figures will also be relevant to gauge overall group health.
No immediate price impact can be assessed from this filing alone, as it is only a submission notice without the underlying numbers. Shareholders should compare the actual reported revenue, operating profit, and EPS against street estimates to judge the stock's reaction.